AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Imfinzi for stage III NSCLC that cannot be removed by surgery (PACIFIC study). On average, people who were treated with Imfinzi lived 16.8 months before their cancer got worse.

IMFINZI with IMJUDO and Platinum-Based Chemotherapy. Infusion-related reactions occurred in 2.9% (17/596) of patients receiving IMFINZI in combination with IMJUDO and platinum-based chemotherapy, ...

Imfinzi and Tecentriq are both drugs used to treat certain cancers. Learn how they’re similar and different to help you decide if one may be right for you.

Imfinzi, which is used to treat some types of cancer, can cause side effects. Learn about common, mild, and serious side effects and how to manage them.

IMFINZI is also approved in the US, the EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer (ES-SCLC) based on the CASPIAN Phase ...

Imfinzi is given by a health care professional in a hospital or clinic. It is given as an infusion into a vein (intravenously). It usually takes about an hour to receive your dose of Imfinzi. ...

Imfinzi and Keytruda are both prescription drugs that treat certain types of cancer. Learn how their uses, effectiveness, and side effects compare.